Common Contracts
4 similar Subscription Agreement contracts by Mateon Therapeutics Inc, Oncotelic Therapeutics, Inc.
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTERSubscription Agreement • July 13th, 2023 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations
This Subscription Agreement (this “Subscription Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Undersigned” or “Subscriber”) in connection with its investment in the securities of Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of 10 and a maximum of 200 Units (the “Units”), each of which consists of one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00 for a period of 2 years from the date of final closing of the Offering, bearing annual interest at the rate of 16%. Each Note will be convertible into 250,000 shares of Oncotelic’s Common Stock (conversion price $0.10 per share), subject to applicable anti dilution provisions. Each Unit will also consist of 250,000 (the “Warrants”), each to purchase one share of Oncotelic’s Common Stock at $0.12 per share. The exercise price of
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTERSubscription Agreement • March 26th, 2021 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
This Subscription Agreement (this “Subscription Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Undersigned” or “Subscriber”) in connection with its investment in the securities of Mateon Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of 40 and a maximum of 100 Units (the “Units”), each of which consists of 25,000 shares of the Common Stock of the Company’s wholly owned subsidiary called EdgePoint AI, Inc., a Delaware corporation (“EdgePoint”), and one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00, bearing annual interest at the rate of 16%. Each Note will be convertible into up to 25,000 shares of EdgePoint’s Common Stock (conversion price $1.00 per share) or up to 138,889 shares of Mateon’s Common Stock (conversion price approximately $0.18 per share), subject to applicable anti d
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTERSubscription Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
This Subscription Agreement (this “Subscription Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Undersigned” or “Subscriber”) in connection with its investment in the securities of Mateon Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of 40 and a maximum of 100 Units (the “Units”), each of which consists of 25,000 shares of the Common Stock of the Company’s wholly owned subsidiary called EdgePoint AI, Inc., a Delaware corporation (“EdgePoint”), and one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00, bearing annual interest at the rate of 16%. Each Note will be convertible into up to 25,000 shares of EdgePoint’s Common Stock (conversion price $1.00 per share) or up to 138,889 shares of Mateon’s Common Stock (conversion price approximately $0.18 per share), subject to applicable anti d
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTERSubscription Agreement • July 29th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
This Subscription Agreement (this “Subscription Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Undersigned” or “Subscriber”) in connection with its investment in the securities of Mateon Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of 40 and a maximum of 100 Units (the “Units”), each of which consists of 25,000 shares of the Common Stock of the Company’s wholly owned subsidiary called EdgePoint AI, Inc., a Delaware corporation (“EdgePoint”), and one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00, bearing annual interest at the rate of 16%. Each Note will be convertible into up to 25,000 shares of EdgePoint’s Common Stock (conversion price $1.00 per share) or up to 138,889 shares of Mateon’s Common Stock (conversion price approximately $0.18 per share), subject to applicable anti d
